Role of epigenetic and miR-22 and miR-29b alterations in the downregulation of Mat1a and Mthfr genes in early preneoplastic livers in rats induced by 2-acetylaminofluorene

Molecular Carcinogenesis

Volumn 52, Issue 4, 2013, Pages 318-327

  Koturbash, Igor ^a   Melnyk, Stepan ^b   James, S Jill ^b   Beland, Frederick A ^a   Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Epigenetics, microRNA; Hepatocarcinogenesis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HISTONE H3; LYSINE; METHIONINE ADENOSYLTRANSFERASE; METHIONINE ADENOSYLTRANSFERASE 1 ALPHA; MICRORNA 22; MICRORNA 29B; N (2 FLUORENYL)ACETAMIDE; UNCLASSIFIED DRUG; CARCINOGEN; HISTONE; MAT1A PROTEIN, RAT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICRORNA; MIRN22 MICRORNA, RAT; MIRN29 MICRORNA, RAT; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FEMALE; GENE CONTROL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; SPRAGUE DAWLEY RAT; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER; LIVER TUMOR; METABOLISM;

RATTUS;

2-ACETYLAMINOFLUORENE; ACETYLATION; ANIMALS; CARCINOGENS; CELL LINE; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; METHIONINE ADENOSYLTRANSFERASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICRORNAS; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE;

MLCS; MLOWN;

EID: 84877291541     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21861     Document Type: Article

References (51)

1. Knudson AG. Cancer genetics. Am J Med Genet 2002; 111: 96-102.
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
3. Bagnyukova TV, Tryndyak VP, Montgomery B, et al. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008; 29: 638-646.
4. Pavanello S, Bollati V, Pesatori AC, et al. Global and gene-specific promoter methylation changes are related to anti-B[a]PDE-DNA adduct levels and influence micronuclei levels in polycyclic aromatic hydrocarbon-exposed individuals. Int J Cancer 2009; 125: 1692-1697.
5. Loeb LA, Harris CC. Advances in chemical carcinogenesis: A historical review and prospective. Cancer Res 2008; 68: 6863-6872.
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
7. Berdasco M, Esteller M. Aberrant landscape in cancer: How cellular identity goes awry. Dev Cell 2010; 19: 698-711.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
9. Ushijima T, Asada K. Aberrant DNA methylation in contrast with mutations. Cancer Sci 2010; 101: 300-305.
10. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N England J Med 2003; 349: 2042-2054.
11. Baylin S, Bestor TH. Altered methylation patterns in cancer cell genomes: Cause or consequence? Cancer Cell 2003; 1: 299-305.
12. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene 2002; 21: 5380-5387.
13. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3: 89-95.
14. Hu JL, Zhou BO, Zhang RR, Zhang KL, Zhou JQ. Xu GL The N-terminus of histone H3 is required for de novo DNA methylation in chromatin. Proc Natl Acad Sci USA 2009; 52: 22187-22192.
15. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40: 741-750.
16. INK4A CpG island is initiated post gene silencing in association with chromatin remodeling and mimics nucleosome positioning. Hum Mol Genet 2009; 18: 3098-3109.
17. Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics 2010; 2: 233-243.
18. French SW. Molecular events in hepatic preneoplasia: A review. Exp Mol Pathol 2010; 88: 219-224.
19. Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010; 70: 277-308.
20. Bitsch A, Hadjiolov N, Klöhn PC, Bergman O, Zwirner-Baier I, Neumann HG. Dose response of early effects related to tumor promotion of 2-acetylaminofluorene. Toxicol Sci 2000; 55: 44-51.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
22. Melnyk S, Pogribna M, Pogribny IP, Yi P, James SJ. Measurement of plasma and intracellular S-adenosylmethionone and S-adenosylhomocysteine utilizing coulometric electrochemical detection: Alterations with plasma homocysteine and pyridoxal-5'-phospahate concentrations. Clin Chem 2000; 46: 265-272.
23. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990-2997.
24. Paul CL, Clark SJ. Cytosine methylation: Quantitation by automated genomic sequencing and GENESCAN analysis. Biotechniques 1996; 21: 126-133.
25. Bannasch P. Preneoplastic lesions as end point in carcinogenicity testing. I. Hepatic preneoplasia. Carcinogenesis 1986; 7: 689-695.
26. Pogribny IP, Muskhelishvili L, Tryndyak VP, Beland FA. The tumor-promoting activity of 2-acetylaminofluorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation. Toxicol Appl Pharmacol 2009; 235: 305-311.
27. Tada M, Yokosuka O, Fukai K, et al. Hypermethylation of NAD(P)H: Quinine oxidoreductase 1(NQO1) gene in human hepatocellular carcinoma. J Hepatol 2005; 42: 511-519.
28. Csepregi A, Ebert MP, Röcken C, et al. Promoter methylation of CDK2A and lack p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010; 10: 317.
29. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000; 19: 5298-5302.
30. Furutani M, Arii S, Tanaka H, et al. Decreased expression and rare somatic mutation of the CIP/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 1997; 111: 191-197.
31. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
32. Pogribny IP, Rusyn I, Beland FA. Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: Studies in rodents. Environ Mol Mutagen 2008; 49: 9-15.
33. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
34. Hong S, Cho YW, Yu LR, Yu H, Veenstra TD, Ge K. Identification of JmjC domain-containing UTX and JMJD3 as histone lysine 27 demethylases. Proc Natl Acad Sci USA 2007; 104: 18439-18444.
35. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modifications. Science 2008; 321: 1084-1085.
36. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
37. Shamron N. MicroRNAs and pharmacogenomics. Pharmacogenomics 2010; 11: 629-632.
38. Stone N, Pangilinam F, Molloy AM, et al. Bioinformatics and genetic association of microRNA target sites in one-carbon metabolism genes. PLoS ONE 2011; 6: e21851.
39. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 2010; 107: 18545-18550.
40. Huang Z, Mato JM, Kanel G, Lu SC. Differential effect of thioacetamide on hepatic methionine adenosyltransferase expression in the rat. Hepatology 1999; 29: 1471-1478.
41. Carretero MV, Latasa MU, Garcia-Trevijano ER, et al. Inhibition of liver methionine adenosyltransferase gene expression by 3-methylcolanthrene: Protective effect of S-adenosylmethionine. Biochem Pharmacol 2001; 61: 1119-1128.
42. Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000; 33: 907-914.
43. Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med 2009; 234: 726-736.
44. Odin E, Wettergren Y, Carlsson G, et al. Expression and clinical significance of methylenetetrahydrofolate reductase in patients with colorectal cancer. Clin Colorectal Cancer 2006; 5: 344-349.
45. Vaissière T, Hung RJ, Zaridze D, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 2009; 69: 243-252.
46. Torres L, Avila MA, Carretero MV, et al. Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: Implications for MAT1A silencing during transformation. FASEB J 2000; 14: 95-102.
47. Torres L, López-Rodas G, Latasa MU, et al. DNA methylation and histone acetylation of rat methionine adenosyltransferase 1A and 2A genes is tissue-specific. Int J Biochem Cell Biol 2000; 32: 397-404.
48. Wang Z, Zang C, Rosenfeld JA, et al. Combinational patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903.
49. Ng HH, Bird A. Histone deacetylases: Silencers to hire. Trends Biochem Sci 2000; 25: 121-126.
50. Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2011 (in press).
51. Calvisi DF, Simile MM, Ladu S, et al. Altered methionine metabolism and global DNA methylation in liver cancer: Relationship with genomic instability and prognosis. Int J Cancer 2007; 121: 2410-2420.